Literature DB >> 25425142

Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future.

Minghuan Jiang1, Zhongliang Zhou, Lina Wu, Qian Shen, Bing Lv, Xiao Wang, Shimin Yang, Yu Fang.   

Abstract

BACKGROUND: In 2009, China implemented the National Essential Medicines System (NEMS) to improve access to high-quality low-cost essential medicines.
OBJECTIVE: To measure the prices, availability and affordability of medicines in China following the implementation of the NEMS.
SETTING: 120 public hospitals and 120 private pharmacies in ten cities in Shaanxi Province, Western China.
METHOD: The standardized methodology developed by the World Health Organization and Health Action International was used to collect data on prices and availability of 49 medicines. MAIN OUTCOME MEASURES: Median price ratio; availability as a percentage; cost of course of treatment in days' wages of the lowest-paid government workers.
RESULTS: In the public hospitals, originator brands (OBs) were procured at 8.89 times the international reference price, more than seven times higher than the lowest-priced generics (LPGs). Patients paid 11.83 and 1.69 times the international reference prices for OBs and generics respectively. A similar result was observed in the private pharmacies. The mean availabilities of OBs and LPGs were 7.1 and 20.0 % in the public hospitals, and 12.6 and 29.2 % in the private pharmacies. Treatment with OBs is therefore largely unaffordable, but the affordability of the LPGs is generally good.
CONCLUSION: High prices and low availability of survey medicines were observed. The affordability of generics, but not OBs, is reasonable. Effective measures should be taken to reduce medicine prices and improve availability and affordability in Shaanxi Province.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25425142     DOI: 10.1007/s11096-014-0037-4

Source DB:  PubMed          Journal:  Int J Clin Pharm


  5 in total

Review 1.  Early appraisal of China's huge and complex health-care reforms.

Authors:  Winnie Chi-Man Yip; William C Hsiao; Wen Chen; Shanlian Hu; Jin Ma; Alan Maynard
Journal:  Lancet       Date:  2012-03-03       Impact factor: 79.321

2.  Essential medicines and human rights: what can they learn from each other?

Authors:  Hans V Hogerzeil
Journal:  Bull World Health Organ       Date:  2006-05-17       Impact factor: 9.408

3.  Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts?

Authors:  Hans V Hogerzeil; Melanie Samson; Jaume Vidal Casanovas; Ladan Rahmani-Ocora
Journal:  Lancet       Date:  2006-07-22       Impact factor: 79.321

4.  Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi province of China.

Authors:  Minghuan Jiang; Shimin Yang; Kangkang Yan; Jun Liu; Jun Zhao; Yu Fang
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

5.  A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.

Authors:  Wenjie Zeng
Journal:  BMC Health Serv Res       Date:  2013-10-05       Impact factor: 2.655

  5 in total
  9 in total

1.  The availability and affordability of orphan drugs for rare diseases in China.

Authors:  Shiwei Gong; Yingxiao Wang; Xiaoyun Pan; Liang Zhang; Rui Huang; Xin Chen; Juanjuan Hu; Yi Xu; Si Jin
Journal:  Orphanet J Rare Dis       Date:  2016-02-27       Impact factor: 4.123

2.  Availability, prices and affordability of UN Commission's lifesaving medicines for reproductive and maternal health in Uganda.

Authors:  Denis Kibira; Freddy Eric Kitutu; Gemma Buckland Merrett; Aukje K Mantel-Teeuwisse
Journal:  J Pharm Policy Pract       Date:  2017-11-15

3.  Evaluating access to oral anti-diabetic medicines: A cross-sectional survey of prices, availability and affordability in Shaanxi Province, Western China.

Authors:  Caijun Yang; Shuchen Hu; Yanbing Zhu; Wenwen Zhu; Zongjie Li; Yu Fang
Journal:  PLoS One       Date:  2019-10-16       Impact factor: 3.240

Review 4.  Towards universal health coverage: achievements and challenges of 10 years of healthcare reform in China.

Authors:  Wenjuan Tao; Zhi Zeng; Haixia Dang; Peiyi Li; Linh Chuong; Dahai Yue; Jin Wen; Rui Zhao; Weimin Li; Gerald Kominski
Journal:  BMJ Glob Health       Date:  2020-03-19

5.  Availability, prices and affordability of essential medicines in Zhejiang Province, China.

Authors:  Zuojun Dong; Qiucheng Tao; Bobo Yan; Guojun Sun
Journal:  PLoS One       Date:  2020-11-24       Impact factor: 3.240

6.  Availability, prices and affordability of essential medicines: A cross-sectional survey in Hanam province, Vietnam.

Authors:  Huong Thi Thanh Nguyen; Dai Xuan Dinh; Trung Duc Nguyen; Van Minh Nguyen
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

7.  Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji.

Authors:  Yunyu Huang; Youfen Jiang; Luying Zhang; Wenhui Mao; Job F M van Boven; Maarten J Postma; Wen Chen
Journal:  BMC Health Serv Res       Date:  2018-03-27       Impact factor: 2.655

8.  Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.

Authors:  Xiaodong Guan; Ye Tian; Dennis Ross-Degnan; Chunxia Man; Luwen Shi
Journal:  BMJ Open       Date:  2018-07-16       Impact factor: 2.692

9.  Use of medicines in São Paulo, Brazil, and State Health Care Coverage, 2003 and 2015.

Authors:  Camila Nascimento Monteiro; Felipe Tadeu Carvalho Santos; Karen Sarmento Costa; Marilisa Berti de Azevedo Barros; Chester Luiz Galvão Cesar; Moisés Goldbaum
Journal:  Clinics (Sao Paulo)       Date:  2021-07-16       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.